DPP4 and type 2 diabetes mellitus: In conclusion, this large nationwide retrospective study indicated that, among T2DM patients with chronic HBV infection, the use of DPP-4 inhibitors was associated with a significantly lower risk of HCC incidence than non-DPP-4 inhibitors use.